Dose key facts
as of Oct 2026- Producer of organic wellness drinks and shots intended to offer functional support for a healthier body every day.
- Dose is valued at approximately $347.0M as of Oct 2026 (last reported valuation).
- It has raised $62.1M; the latest was Later Stage VC ($47.0M) in May 2025.
- Notable investors include Unilever Ventures, Melitas Ventures, Vanterra Ventures.
- Status: Privately Held (backing).
Dose's last reported valuation, May 2025. Nothing priced has surfaced since.
- ·Watch Dose: the Monday email on marks, rounds and moves
Dose funding rounds
No funding rounds for Dose are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Dose
3Dose valuation
Dose's last reported valuation was $347 million in May 2025. No priced round, secondary trade or fund mark has surfaced since.
Dose investors
3 investors are on record for Dose, including Unilever Ventures, Melitas Ventures and Vanterra Ventures.
About Dose
Producer of organic wellness drinks and shots intended to offer functional support for a healthier body every day. The company's products include turmeric, aloe vera, elderberry, and milk thistle, which benefit the liver, skin, immune system, and muscles, providing customers with shots that contain potent ingredients that help them to keep their bodies healthy.
- Sector
- Consumer Products and Services (B2C)
- HQ
- Ontario, CA, United States
- Founded
- 2020
- Employees
- 14
- Website
- dosedaily.co/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.